Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to find out what effects, good and/or bad, 2 doses of Cetuximab will have on head and neck cancer. The study is done because 250 mg/m2 given weekly does not work very well. Doses as high as 700 mg/m2 every other week appear to be no more toxic, so we will try to determine if 500 mg/m2 and 750 mg/m2 given every other week can work better. We do not know if it will help. We can use what we learn from this research study to help other people with the same disease.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT00661427
Study type Interventional
Source Memorial Sloan Kettering Cancer Center
Contact
Status Completed
Phase Phase 2
Start date November 2007
Completion date August 2012

See also
  Status Clinical Trial Phase
Not yet recruiting NCT06398418 - R-5780-01 In Combination With PD-1 Checkpoint Inhibitors (Checkpoint Protein on Immune Cells Called T Cells) in Patients With Solid Tumors Phase 1
Completed NCT01358097 - Role of Immune Activation in Response of Head and Neck Squamous Cell Carcinoma to Therapy N/A
Completed NCT00705016 - Cilengitide in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) Phase 1/Phase 2
Active, not recruiting NCT04116320 - Focused Ultrasound Ablation and PD-1 Antibody Blockade in Advanced Solid Tumors Phase 1
Completed NCT01721525 - Induction Chemotherapy With Afatinib, Ribavirin, and Weekly Carboplatin/Paclitaxel for Stage IVA/IVB HPV Associated Oropharynx Squamous Cell Cancer (OPSCC) Phase 1
Completed NCT01016769 - Temsirolimus + Weekly Paclitaxel + Carboplatin for Recurrent or Metastatic Head and Neck Squamous Cell Cancer (HNSCC) Phase 1/Phase 2
Completed NCT00382031 - Zalutumumab in Patients With Non-curable Head and Neck Cancer Phase 3
Recruiting NCT04391049 - Testing the Addition of the Anti-cancer Viral Therapy Telomelysin™ to Chemoradiation for Patients With Advanced Esophageal Cancer and Are Not Candidates for Surgery Phase 1
Recruiting NCT05932511 - Topical Ascorbic Acid for Treatment of Squamous Cell Skin Cancer Early Phase 1
Completed NCT00815295 - Study of Sorafenib/Cetuximab in Head and Neck Cancer Phase 1/Phase 2
Completed NCT00542308 - Zalutumumab in Non-curable Patients With SCCHN Phase 2
Completed NCT00485485 - Imatinib Mesylate (Gleevec) and Docetaxel in Patients With Head and Neck Squamous Cell Cancer Phase 2
Terminated NCT02376699 - Safety Study of SEA-CD40 in Cancer Patients Phase 1
Completed NCT00255476 - The IRESSA Novel Head and Neck Chemotherapy Evaluation Study Phase 2
Recruiting NCT03935893 - Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers Phase 2
Terminated NCT00401401 - Zalutumumab in Combination With Chemotherapy and Radiotherapy in Head and Neck Cancer Phase 1/Phase 2
Terminated NCT00559351 - RCT on the Combined Modality Treatment of Squamous Cell Carcinoma of the Esophagus Phase 3
Active, not recruiting NCT03370276 - Cetuximab & Nivolumab in Patients With Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma Phase 1/Phase 2
Completed NCT03509467 - Using MC1R Genotype to Impact Melanoma Risk Behavior N/A
Completed NCT01384708 - Evaluation of a Miniaturized Microscope Device for the Detection of Esophageal Squamous Cell Cancer Phase 0